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Summary Safety of administration of a vindesine (VDS)-anti-CEA conjugate and its ability to localise after
radiolabelling were investigated in patients with advanced metastatic carcinoma (4 colorectal and 4 ovarian).
For imaging, patients received between 230 and 520pg of 131I labelled antibody. In 5, localisation of
conjugate was demonstrated, in another it was equivocal and in 2 patients, undetectable. For assessment of
safety each patient also received a single dose ofconjugate increasing from 1.2 to 42mg antibody linked to 24
to 1800 g VDS. The in vitro activity of the anti-CEA antibody and its ability to localise in vivo were
preserved after conjugation. There was no obvious toxicity or hypersensitivity attributable to either the
radiolocalisation or escalated doses of conjugate in any of the patients. The feasibility of the preparation and
administration to patients of a vindesine-antibody conjugate has been demonstrated.
The concept of targeting drugs on to malignant
cells proposed by Ehrlich (1900) offers a potential
improvement over one of the major limitations of
cancer chemotherapy, viz. the limited selectivity of
drugs for cancer cells. The use of antibodies as
carriers was tested experimentally in an L1210
leukaemia (Mathe et al., 1958) and clinically in
malignant melanoma (Ghose et al., 1972).
Despite reports of some success with this
approach it has not been widely adopted. This has
been partly due to the inability to demonstrate
tumour-specific antigens as targets in human
tumours; however, in order to increase the
therapeutic index of a drug, differential expression
of the target by the tumour compared to normal
tissue may be sufficient. The well characterised
tumour-associated antigens, carcinoembryonic
antigen (CEA) and alpha fetoprotein (AFP), offer
such potential targets in man. Another reason for
caution with this approach has been scepticism
about the in vivo stability of the drug and antibody
conjugate. It was demonstrated in the mouse EL4
lymphoma model, that drug and antibody were
interactive and more effective than a conjugate of
the two (Davies & O'Neill, 1973). This led to a
pilot study of drug and antibody interaction in
patients with resected bronchogenic carcinoma
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(Newman et al., 1977) and to studies of a variety of
drug and antibody conjugates and intermediate
carriers (Ghose & Blair, 1978; Lee & Hwang, 1979;
Dullens & De Weger, 1980, and Rowland, 1982).
The demonstration of enhanced toxicity of
vincristine for a CEA-secreting lung cancer cell line
in the presence of anti-CEA-immunoglobulin (Ig)
(Johnson et al., 1980) encouraged us to investigate
direct conjugation of vinca alkaloids to antibody.
The toxicity of vindesine for a CEA-secreting cell
line was found to be greatly increased when
conjugated to an anti-CEA-Ig (Johnson et al.,
1981). The aims of the present study were to
investigate the ability to localise and safety of
administration of this conjugate in patients with
advanced metastatic adenocarcinomas refractory to
established forms of treatment.
Materials and methods
Patients
Eight patients with advanced metastatic carcinoma
refractory to previous treatment were entered into
this study; all gave informed consent. Patients
selected had tumour types likely to express CEA
and to localise anti-CEA-antibodies (Goldenberg et
al., 1978a; Dykes et al., 1980; Van Nagell et al.,
1980). Four had disseminated ovarian carcinomas
and 4 had disseminated colorectal carcinomas.
Before injection of radio-labelled antibody, patients
were tested for immediate and delayed
hypersensitivity to sheep Ig (0.1 ml of mgml-1).
When there was a delay of more than a week
between the first dose of conjugate and the next
dose sensitivity testing was repeated. To block
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thyroid uptake of 131I, potassium iodide tablets
(180mgday-1) were given, beginning 1-3 days
before administration of the iodinated
conjugate/antibody and continuing for 8-12 days
thereafter.
Patients were admitted to hospital 1-3 days prior
to the study for complete physical examination,
baseline laboratory investigations and
hypersensitivity testing. Venous blood was sampled
for full blood count, urea and electrolytes,
biochemical profile and GTs. Twenty-four hour
creatinine clearances were also performed.
Temperature, blood pressure and pulse were
recorded half-hourly during and for 4-6h
immediately after infusion of conjugate and every
4h thereafter. Subjective toxicity was monitored
daily by the attending physician (JRJ) and routine
follow-up investigations performed every 1-2 days
for the first 10-14 days. Particular attention was
paid to evidence of hypersensitivity reactions and
neurological status on clinical examination. Patients
were then followed up in the clinic at weekly
intervals for a minimum of 1 month, and in most
cases 2-3 months.
Antibody
Immunoglobulin (Ig) was prepared from sheep anti-
CEA serum by ammonium sulphate precipitation
and was provided by Dr. A.R. Bradwell,
Immunodiagnostics Research Laboratory,
University of Birmingham, U.K. The antibody had
been absorbed with normal liver, colon, lung and
spleen. In fused rocket immunoelectrophoresis it did
not recognise the CEA cross-reacting determinants
shared with the non-specific cross-reacting antigen
(NCA). Localisation of this antibody to human
gastrointestinal tumour deposits has been reported
(Dykes et al., 1980). In our hands it localised on
sections of a formalin-fixed CEA-secreting colonic
carcinoma in an indirect immunoperoxidase test at
a titre of 1/80,000. However, in the
immunocytochemical tests there was still residual
antibody activity to shared NCA determinants as
demonstrated by staining of chronic myeloid
leukaemia cells and splenic myeloid cells (Ford et
al., 1981).
Conjugate
Vindesine (VDS)-anti-CEA Ig conjugates were
prepared at Lilly Research Centre Ltd. from
desacetylvincaleucoblastine acid hydrazide under
aseptic conditions by a modification of the
procedure described for vindesine-BSA (Conrad et
al., 1979) and purified by gel filtration. Four batches
were prepared with initial conjugation ratios of 4.1,
5.4, 4.3 and 11 moles vindesine per mole IgG. An
iodinated aliquot of Batch I was used to scan
patients 1 and 2. Iodinated Batch II was used to
scan patients 3-6. Patients 7 and 8 were scanned
with an iodinated aliquot of the sheep anti-CEA Ig
used to prepare Batch IV.
For assessment of safety, patients received doses
of 1.2-42mg conjugate, containing 24-1800pg VDS,
injected i.v. in 100ml of 1% human serum albumin
in saline (HSA-saline) over a 30-60min period. All
conjugates were 0.22pm filtered before dilution in
sterile, HSA-saline.
Radiolabelling ofconjugate/antibody
Aliquots of batches of conjugate (or antibody) were
iodinated with 1311 using a modified chloramine-T
method (Garvey et al., 1977). Free iodine was
removed on a Sephadex G-25 column which was
eluted with HSA-saline. Fractions containing the
protein peak as determined by y-counting were
pooled and sterile filtered through a 0.22,pm filter.
Radiolabelled conjugate (or antibody) was injected
i.v. in 100ml of sterile HSA-saline over a 30-60min
period.
All solutions were tested for pyrogenicity and
sterility. lodinated conjugates were tested at
6pgIgkg-1 body weight in rabbits and uniodinated
conjugates were tested from 45-198pgIgkg-1
body weight depending on the dose to be
administered to patients. All batches were negative.
Photoscanning
Between 230-520pgIg conjugate (6-14pg of VDS)
containing 541-1014pCi protein bound 131I was
administered to patients 1-6. Patients 7 and 8 each
received 471pg of unconjugated Ig containing
1056pCi 1311.
Each patient received i.v. 99mTc-pertechnetate
(500pCi) 30min before each scan, and 99mTc-
labelled human serum albumin (500pCi) 5min
before each scan. These distribute similarly to free
iodide and radiolabelled antibody respectively in
the blood pool. Images of the chest and abdomen
were obtained with a gamma camera (Searle LFOV
with medium energy collimator) initially at 4, 24
and 48h after injection of iodinated material. The
4h scans were discontinued for patients 3-8. The
camera was linked to a DEC PDP11/40 computer
with a dual isotope facility and a colour scale visual
display unit. The data were stored and displayed in
a 64 x 64 matrix. After normalising over the cardiac
area, subtraction of the technetium component from
the iodine component was performed to visualise
areas of selective uptake of conjugate.
Measurement ofanti-CEA activity
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(ELISA) (Woodhouse et al., 1982) was used to
measure anti-CEA activity of antibody, conjugate
and iodinated conjugate. Briefly, disposable cuvettes
were coated with purified CEA, washed, blocked by
incubation with BSA, washed and the test sample
added, before incubation at 35°C for 3h. Following
a further washing, rabbit anti-sheep IgG
horseradish peroxidase conjugate (Nordic, U.K.)
was added. The cuvettes were incubated at 35°C for
3h, washed and then ABTS (2.2-azino-di-(3-
ethylbenzthiazoline sulphonic acid) (Sigma)) was
added. Absorbance at 405nm was measured using a
Gilford PR-50 processor-reader.
Measurement ofserum CEA levels
CEA measurements were performed by Dr. P.
Gosling, East Birmingham Hospital, using a
modified double antibody technique (Booth et al.,
1973). Serum samples were perchloric acid-extracted
before assay.
Results
The dosages of radiolabelled conjugate/antibody
and uniodinated conjugate received by each patient
are given in Table I.
Details of the patients in this study and the
scanning results are summarised in Table II.
Patients 1-6 received radiolabelled conjugate,
followed within 4-54 days by unlabelled conjugate.
Localisation of radioactivity which equated with
clinically detectable disease was seen in patients 1,
2, 3, 4 & 6. The localisation picture for patient 5
was equivocal. Figures 1 and 2 illustrate localisation
images. Figure 1 is the 48h subtraction scan for
patient 2 who had a large abdomino-pelvic mass
which was confirmed on CT scans. Localisation of
isotope occurred in the mass and in the right
kidney. Subsequent investigation of this patient by
intravenous pyelography indicated a right
hydronephrosis due to compression of the right
ureter by the tumour. Impaired excretion
apparently resulted in an accumulation of isotope in
the right kidney.
Figure 2 is the 48h subtraction scan for patient 6
who had an extensive pelvic tumour mass and
central palpable abdominal masses. Ultrasound
examination confirmed the presence of enlarged
para-aortic and coeliac axis nodes. Localisation of
isotope coinciding with these, and the pelvic mass
at the primary site, can be seen in Figure 2.
For practical reasons, the last 2 patients received
uniodinated conjugate and then radiolabelled
unconjugated antibody. There was no evidence of
localisation in these patients (see Discussion).
The relative anti-CEA activities of the non-
iodinated conjugates in ELISA compared to the
original antibody, when tested within 14 days of
conjugation, were: Batch I, 98%; Batch II, 100%;
Batch III, 80%. In the case of Batch IV it was not
possible to obtain a relative anti-CEA value. After
iodination the values were: Batch I, 48%; Batch II,
72%. Batches III and IV were not iodinated and the
radiolabelled antibody used for patients 7 and 8
had 70% activity.
With the exception of patient 6, all had raised
(>15ngml-1) pretreatment serum CEA levels
(Table 2). We noted no significant decline in CEA
levels in any of the patients after the radiolocalising
dose. One day after administration of 11.06mg
VDS-Ig conjugate to patient 3, there was a fall from
31-17ngml-' which was sustained for 3 days.
Similarly, for patient 6, who developed a raised
CEA level of 37ngml-1 from a pre-treatment value
Table I Summary of dosages
Iodinated antibody Non-iodinated antibody
VDS Ig 1311* VDS Ig
Patient ug 9g pCi pg mg
1 6 300 996 24.5 1.2
2 6 300 541 30.3 1.5
3 6.25 230 1014 300.8 11.06
4 6.5 240 581 300.8 11.06
5 14.1 520 633 722 33.4
6 14.1 520 633 722 33.4
7 471 1056 924.4- 20.9-
8 471 1056 1849t 41.8t
*protein-associated radioactivity.
Idose given was within this estimated range-see Discussion.38 C.H.J. FORD et al.
Table II Summary ofclinical localisation data
Pre-treatment
Summary ofdisease serum CEA Scan localisation
Case Origin ofprimary at entry level (ngml-1) findings
1 Colon, Duke's C, well-
differentiated
adenocarcinoma
2 Ovarian, FIGO IV
mucinous
cystadenocarcinoma
3 Ovarian, FIGO III
moderately well-
differentiated
adenocarcinoma
4 Ovarian, FIGO
III-IV
adenocarcinoma
5 Ovarian, FIGO III
papillary
cystadenocarcinoma
6 Recto-sigmoid, Duke's
C, well-differentiated
adenocarcinoma
7 Rectum, Duke's C,
mucinous
adenocarcinoma
8 Caecum, Duke's C,
adenocarcinoma
Widespread intra
pulmonary metastases;
pelvic and hepatic
metastases
Palpable abdomino-
pelvic mass;
left axillary
nodes; left
cervical nodes
Mass in right
groin; large
left pelvic mass
Left malignant
pleural effusion;
malignant peritoneal
seedlings
Pelvic recurrence
Extensive pelvic mass
(biopsy proven
adenocarcinoma)
and central
palpable
abdominal masses
Perineal recurrence
biopsy proven
Retroperitoneal tumour,
biopsy proven
>3,550 Uniform liver (4h);
two small abdominal
areas (48h)
375 Liver (4h; 24h);
left axillar;
right kidney;
abdomino-pelvic
mass (48h)
29 Central lower
abdomen (48h)
23 Left chest (48h);
scattered areas
in abdomen
and pelvis (48h)
32 Medial to upper
part of stomach
scattered abdominal
areas (48h)
13 Central abdominal
and pelvic
localisation (48h)
43 *No localisation
749 *No localisation
*See text for details.
of 13 ngml-1, one day after receiving 33.4mg VDS-
Ig conjugate this level fell to 22ngml-'. Five days
later the CEA level began to increase. In the other
patients no change was observed.
None of the patients had immediate or delayed
hypersensitivity reactions to normal sheep Ig, either
before the first or second dose of conjugate, nor any
reaction to the conjugate. The period between
conjugation and administration of the localising
dose was 6-20 days; between conjugation and
administration of escalated dose was 3-25 days, and
the time between localising and escalated doses was
4-54 days. Patients 7 and 8 received unconjugated
antibody 8 and 6 days respectively before they
received conjugate.
In none of the 8 patients was there any toxicity
or derangement of biochemical, renal or liver
function which had not been present at entry into
the investigation and which could be attributed to
the administration of conjugate. Liver function
became increasingly abnormal during follow-up in
patient 3. Patient 6 developed obstructive jaundiceA VINDESINE ANTI-CEA CONJUGATE IN VIVO 39
Figure 1 48h abdominal subtraction scan for Patient 2, showing accumulation of isotope in the right kidney
(k) and in the abdomino-pelvic tumour mass (-+). Accumulation of isotope, in the form of free iodide, can be
seen in the stomach at the top of the scan.
Figure 2 48h abdominal subtraction scan for Patient 6, showing accumulation of isotope in the pelvic
tumour mass (p) and in the central abdominal masses (-+). Accumulation of isotope, in the form of free iodide,
can be seen in the stomach at the top of the scan.40 C.H.J. FORD et al.
and deranged liver function between the first and
second administration of conjugate which was due
to enlarged metastatic lymph nodes in the porta
hepatis and para-aortic areas. Progressive
gastrointestinal obstruction was noted in patients 1
and 3 and was attributable to neoplastic adhesions
which were confirmed at laparotomy for patient 1.
Progressive pelvic recurrence was noted in patient 5
during the study. Five of the patients were anaemic
(3, 4, 5, 7 and 8) and only in the last patient was
this progressive. Two patients (4 and 8) also had a
short-lived thrombocytosis. In no case was the
abnormal renal function in patients 1, 3, 4 and 5
further impaired by administration of conjugate.
Also, the cis-platinum-related peripheral sensory
neuropathy in patient 4 apparently improved
during the investigation.
Three days after receiving radiolabelled conjugate
patient 1 underwent sigmoidoscopy and biopsies of
tumour and normal rectal tissue were obtained.
These were weighed and the radioactivity measured
in a y-counter. The ratio of normal:tumour (N:T)
counts was 1:1.2. The tissues were then macerated
with a scalpel blade, weighed, washed 3 x with
RPMI 1640 and the counts remeasured. The N:T
ratio was 1:4.6. One week after receiving
radiolabelled conjugate this patient had a
laparotomy and was found to have numerous
adhesions and liver secondaries. A colostomy was
performed and biopsies taken of "normal" and
metastatic hepatic tissue. Following the same
procedure as before the N:T ratio was 1:0.6.
Discussion
One of the aims of this study was to determine
whether radio-localisation of "3'1-labelled VDS-
anti-CEA could be achieved in human tumours.
This was clearly demonstrated in 4/8 patients (2, 3,
4 & 6). Overall, the scanning results for Patient 1
were also consistent with localisation. However, the
uniform uptake in the liver at 4h may have been
due to liver secondaries, or, alternatively, to
deposition of anti-CEA/CEA immune complexes
(pre-treatment CEA level of >3,550ngml-1). The
latter possibility is strengthened by the N:T ratio of
radioactivity in the liver of 1:0.6. The two isolated
abdominal areas showing localisation at 48h
equated with the neoplastic adhesions seen at
laparotomy. The pelvic and pulmonary metastases
did not show localisation. In patient 5 localisation
was equivocal. Patients 7 and 8 were given
conjugate first, then scanned with radiolabelled
unconjugated antibody, and neither showed
convincing localisation. There are a number of
possible explanations for this. Firstly, that the
patients' tumours were not producing CEA. The
pretreatment serum CEA levels of 43 and
749ngml-' would argue against this. Secondly,
avascularity could have reduced access of the
conjugate to the tumour, resulting in false negativity
as suggested by others (Dykes et al., 1980).
However, we favour the third possibility which is
that the CEA binding sites had been saturated by
the administration of conjugate prior to receiving
the radiolocalising dose. Both patients received up
to 42mg of conjugated Ig 8 and 6 days respectively
before their radiolocalising dose (Table 1).
Our results suggest that drug conjugation has
destroyed neither the activity of the anti-CEA
antibody in vitro, nor its ability to localise in vivo.
Most of the antibody activity was retained after
conjugation as demonstrated by ELISA and the
doses of conjugate required for localisation were
similar to doses of unconjugated antibody reported
by others (Goldenberg et al., 1978a; Dykes et al.,
1980; Mach et al., 1980). Furthermore, there was an
N:T radioactivity ratio of 1:4.6 at 3 days in a biopsy
of the colonic tumour from patient 1.
There was no obvious toxicity or hypersensitivity
attributable to administration of either
radiolocalising or escalated doses of conjugate in
any of the eight patients. There were abnormalities,
e.g. in liver function, during the course of the study,
but none could be directly attributed to the
conjugate. Most could be explained by the fact that
the patients had advanced disease and had
previously undertaken several different treatment
programmes. The maximum dose of conjugated
drug we administered was 0.9-1.8mg on a single
occasion, which is less than the conventional
therapeutic dose of vindesine of 3-4mgm 2 every 1-
2 weeks (Yap et al., 1981; Cobleigh et al., 1981), or
4-5mgm-' every 2 weeks (Valdivieso et al., 1981b).
However, since the conjugate had been shown to be
-% 25 times as potent as free VDS against lung
cancer cells in vitro (Johnson et al., 1981; Rowland
et al., 1982a), we felt justified in taking a cautious
approach when investigating it in patients.
Overall there was no significant decrease in
circulating CEA levels due to the administration of
either dose ofconjugate. Whilst Patients 3 and 6 did
show decreases (31-17ngml-1 and 37-22ngml-1
respectively), fluctuations similar to these were
noted at other times and did not appear to be
treatment related.
Whilst we have clearly demonstrated the
feasibility of this approach a number of problems
were noted. The most important was aggregation of
Batches III and IV, forcing us to change our plan of
investigation. For Batch III 80% relative anti-CEA
activity was used to calculate the amount of
conjugate given. However, for Batch IV it was notA VINDESINE ANTI-CEA CONJUGATE IN VIVO 41
possible to do this. We estimate the dose given was
within the 5O-100% range. The reason for
aggregation remains unexplained at present. A
possible factor may have been the higher
conjugation ratio of 11:1 achieved with Batch IV. A
single batch of conjugate was not used for the entire
study in order to minimise the time between
conjugation and administration of both
radiolocalising and escalated doses, since a loss of
anti-CEA activity of the conjugate had been noted
in vitro after storage at 4°C for more than 31 days
(Johnson et al., 1981). The longest period between
conjugation and administration of conjugate in the
present study was 25 days.
CEA was chosen as a model for this investigation
because, by immunocytochemistry, it has been
shown to be expressed by 62% of colonic
carcinomas (Goldenberg et al., 1978b), 62% of
gastric carcinomas (Lee et al., 1978), 63% of
invasive cancers of the cervix (Van Nagell et al.,
1979), and 82% of lung cancers (Ford et al., 1981).
Also, 100% of primary and 67% of metastatic
ovarian carcinoma sites have been shown to localise
anti-CEA antibodies in vivo (Van Nagell et al., 1980)
and successes have been achieved with other
tumours (Goldenberg et al., 1978a; Dykes et al.,
1980; Mach et al., 1980), although, as in this study,
not all tumour sites in a patient and not all patients
have shown localisation. CEA, therefore, is a
potential target applicable to a variety of human
cancers.
Vindesine is active in small cell anaplastic
carcinoma of the lung (Osterlind et al., 1981),
colorectal (Valdivieso et al., 1981a) and breast
carcinomas (Yap et al., 1981; Cobleigh et al., 1981).
Since it is feasible to make conjugates of vindesine
with antibody, VDS-anti-CEA conjugates are
candidates for clinical evaluation of possible
therapeutic effect. Questions that also require
resolution and which are the subject of
investigation are whether the conjugate is stable in
vivo and whether administration of conjugate
actually results in increased tissue levels of drug in
the target tissue. We are exploring this potential
further in vitro and in vivo using polyclonal and
monoclonal VDS-antibody conjugates (Rowland et
al., 1982ab). Clinical use of monoclonal conjugates
should be acceptable in view of the reports of
successful administration of monoclonal antibodies
to patients (Nadler et al., 1980; Miller & Levy,
1981).
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